<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231969</url>
  </required_header>
  <id_info>
    <org_study_id>BOFT-0117/DR-CAC</org_study_id>
    <nct_id>NCT03231969</nct_id>
  </id_info>
  <brief_title>A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model</brief_title>
  <official_title>A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2, Dose Ranging Evaluation of the Effectiveness of Bilastine Ophthalmic Solution (0.2%, 0.4%, and 0.6%) Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faes Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Faes Farma, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to&#xD;
      vehicle for the treatment of the signs and symptoms of allergic conjunctivitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Actual">October 11, 2017</completion_date>
  <primary_completion_date type="Actual">October 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Efficacy assessment period (Day 1 through Day 22)</time_frame>
    <description>subjects will assess their ocular itching post-CAC on a 0-4 scale</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Bilastine 0.2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilastine 0.4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilastine 0.6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilastine 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine 0.2%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 25 day period.</description>
    <arm_group_label>Bilastine 0.2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine 0.4%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 25 day period.</description>
    <arm_group_label>Bilastine 0.4%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine 0.6%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 25 day period.</description>
    <arm_group_label>Bilastine 0.6%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine 0%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 25 day period.</description>
    <arm_group_label>Bilastine 0%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  be at least 18 years old&#xD;
&#xD;
          -  be willing and able to avoid all disallowed medications and contact lenses&#xD;
&#xD;
          -  must have a pregnancy test if of childbearing potential&#xD;
&#xD;
          -  must be able to read an eye chart from 10 feet away&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  must not have any allergies to the study medications&#xD;
&#xD;
          -  must not have any ocular or non ocular condition that investigator feels will&#xD;
             interfere with study parameters&#xD;
&#xD;
          -  must not have used immunotherapy in the last 2 years&#xD;
&#xD;
          -  must not have used an investigational drug or device in the past 30 days or&#xD;
             concurrently enrolled in another investigational trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ora Clinical Research Center</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <disposition_first_submitted>October 25, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 25, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 26, 2018</disposition_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 9, 2021</submitted>
    <returned>April 1, 2021</returned>
    <submitted>October 28, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

